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In primary mouse embryo fibroblasts (MEFs), oncogenic Ras induces growth arrest via Raf/MEK/extracellular signal-regulated kinase (ERK)-mediated activation of the p19ARF/p53 and INK4/Rb tumor suppressor
pathways. Ablation of these same pathways causes spontaneous immortalization in MEFs, and oncogenic
transformation by Ras requires ablation of one or both of these pathways. We show that Kinase Suppressor of
Ras 1 (KSR1), a molecular scaffold for the Raf/MEK/ERK cascade, is necessary for RasV12-induced senescence,
and its disruption enhances primary MEF immortalization. RasV12 failed to induce p53, p19ARF, p16INK4a, and
p15INK4b expression in KSR1ⴚ/ⴚ MEFs and increased proliferation instead of causing growth arrest. Reintroduction of wild-type KSR1, but not a mutated KSR1 construct unable to bind activated ERK, rescued
RasV12-induced senescence. On continuous culture, deletion of KSR1 accelerated the establishment of spontaneously immortalized cultures and increased the proportion of cultures escaping replicative crisis. Despite
enhancing escape from both RasV12-induced and replicative senescence, however, both primary and immortalized KSR1ⴚ/ⴚ MEFs are completely resistant to RasV12-induced transformation. These data show that
escape from senescence is not necessarily a precursor for oncogenic transformation. Furthermore, these data
indicate that KSR1 is a member of a unique class of proteins whose deletion blocks both senescence and
transformation.

cells allows for a bypass of RasV12-induced senescence (4, 6,
28, 29, 70). This could be due to both differences in regulation
of the INK4a/ARF locus between mouse and human cells and
the relative importance of different INK4 family members in
mouse cells.
RasV12 induces expression of both p16INK4a and p19ARF in
primary mouse fibroblasts (50, 59), but RasV12 cannot induce
p14ARF expression in human fibroblasts (21, 69). Differences in
regulation of the INK4a/ARF locus in human and mouse cells
are not completely understood. p15INK4b, a related INK4 family member, is also regulated by RasV12 in mouse fibroblasts.
p15INK4b is up-regulated by RasV12, and deletion of p15INK4b
abrogated RasV12-induced senescence in primary mouse embryo fibroblasts (MEFs) (40, 43). These data indicate that
members of the INK4 family of proteins are important regulators of RasV12-induced senescence in both mouse and human
fibroblasts.
Expression of constitutively activated Raf, constitutively activated MEK, or Ras effector loop mutants that activate Raf
has shown that both the senescence-promoting (20, 41, 76) and
oncogenic (12, 24, 44, 54, 68, 71) properties of RasV12 can be
replicated by activation of the Raf/MEK/ERK cascade. Expression of constitutively activated Raf or MEK in primary
mouse or human fibroblasts causes cell cycle arrest, induction
of p53 and p16INK4a, and expression of senescence-associated
(SA) ␤-galactosidase activity (20, 41, 76). Growth arrest induced by the Raf/MEK/ERK cascade relies primarily upon p53
signaling. The ability of constitutively activated Raf to cause
growth arrest is dependent upon its ability to induce expression
of p21CIP1 (60, 72). Furthermore, Raf/MEK/ERK signaling

The Raf/MEK/extracellular signal-regulated kinase (ERK)
cascade is one of several growth-regulatory pathways directly
downstream of the small G-protein Ras. Ras was first identified as the transforming agent in Harvey murine sarcoma virus
(63). Subsequent studies showed that mutations in Ras family
members can lead to their constitutive activation, and these
activated Ras proteins could be found in a variety of human
cancers (3, 14, 51). In mammalian fibroblasts, activated Ras
can cause either transformation or irreversible growth arrest,
depending on the cellular context and the expression of cooperating oncogenes (11, 39, 59).
In primary murine fibroblasts, mutationally activated Ras
(RasV12) leads to an irreversible growth arrest characterized by
up-regulation of the tumor suppressor proteins p53 and
p19ARF and the cyclin-dependent kinase inhibitor p16INK4a
(50, 59). Primary cells arrested by activated Ras are phenotypically indistinguishable from those arrested by continuous culture (9, 27, 59). These cells have an enlarged, flattened morphology, stop proliferating at subconfluent cell densities, and
express several markers of replicative senescence (59). In
RasV12-expressing cells, inactivation of the p19ARF/p53 pathway, either genetically or by introduction of viral oncogenes
that inactivate p53-mediated growth arrest, bypasses cellular
senescence and leads to transformation (22, 34, 39, 50, 58, 59).
While deletion of p16INK4a does not bypass RasV12-induced
senescence in murine cells, disruption of p16INK4a in human
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KSR1 IS A MODIFIER OF SENESCENCE

MATERIALS AND METHODS
Cell culture. Cells were maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 0.1 mM minimal
essential medium nonessential amino acids, 1% penicillin-streptomycin, and 55
M ␤-mercaptoethanol. Cells were incubated at 37°C in 5% CO2.
Construction and production of recombinant retroviruses. KSR1-FLAG,
KSR1.C809Y-FLAG, and KSR1.FSFP/AAAP-FLAG were subcloned from the
EcoRI and SalI sites of pCMV5 (33) into the EcoRI and XhoI sites of MSCVIRES-GFP. MSCV-IRES-GFP, MSCV-KSR1-IRES-GFP, MSCV-KSR1.C809YIRES-GFP, MSCV-KSR1.FSFP/AAAP-IRES-GFP, pBabePuroRasV12, pBabePu
roMEKEE, or pBabePuro retroviral vectors were cotransfected with an ecotropic
packaging vector into 293T cells. At 48 to 72 h posttransfection, viral supernatants
were collected and filtered. Viral supernatants were then either stored at ⫺80°C or
used immediately to infect cells. Puromycin-resistant cells were selected with 4 g/ml
puromycin (Sigma).
Generation of cell lines. Nonimmortalized MEFs were generated from day
13.5 KSR1⫺/⫺ and KSR1⫹/⫹ embryos as previously described (49). To assess
cellular immortalization, cells were maintained in culture under a 3T9 protocol
(67) until immortalized populations of cells emerged. To assess immortalization
of MEFs after plating at low density, 2 ⫻ 104 passage 9 KSR1⫺/⫺, KSR1⫹/⫺, or
KSR1⫹/⫹ MEFs were seeded in a 60-mm dish and fed for 4 weeks until immortalized colonies emerged. To produce KSR1⫺/⫺ MEFs expressing ectopic KSR1
constructs, KSR1⫺/⫺ MEFs were infected with MSCV-KSR1-IRES-GFP,
MSCV-KSR1.C809Y-IRES-GFP, MSCV-KSR1.FSFP/AAAP-IRES-GFP, or
MCSV-IRES-GFP control vector. Fluorescence was detected by flow cytometry,
and cells were separated for low-positive levels of fluorescence. Cells were excited at
488 nm and separated at 530/20 nm, with the baseline fluorescence of uninfected
cells having a mean intensity of 6 (range, 0 to 15), and KSR1-expressing cells having

a mean intensity of 63 (range, 21 to 101). Postsorted cells were assessed for purity by
fluorescence-activated cell sorter (FACS) analysis. Collected pools of cells were
grown in culture and assessed for KSR1 expression level by Western blotting.
Proliferation studies. To assess cellular senescence, cells were seeded at 1 ⫻
104 cells per well in 24-well plates or 5 ⫻ 104 cells per 35-mm dish. Triplicate
dishes were counted 3 h after seeding to account for plating discrepancies and
were then assessed every 48 to 72 h for total cell number on a Beckman Coulter
Counter or by trypan blue exclusion. To assess low-density growth during immortalization, cells were seeded at 2 ⫻ 104 cells per 35-mm dish. Triplicate dishes
from three independent KSR1⫺/⫺ and KSR1⫹/⫹ cultures were counted 3 h after
seeding to account for plating discrepancies and were then assessed every 24 h
(passages 5, 10, and 15) or every 72 h (passage 18) for total cell number on a
Beckman Coulter Counter.
SA ␤-galactosidase activity. SA ␤-galactosidase activity was measured as previously described (16). Briefly, cells were washed twice with phosphate-buffered
saline (PBS) and fixed for 5 min in 2% formaldehyde–0.2% glutaraldehyde,
washed twice with PBS, and stained with SA ␤-galactosidase staining solution
(1 mg/ml X-gal [5-bromo-4-chloro-3-indolyl ␤-D-galactosidase] [stock of 20 mg/ml
in dimethylformamide], 40 mM citric acid-sodium phosphate [pH 6.0], 5 mM
potassium ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, and 2 mM
MgCl2). Cells were incubated overnight at 37°C in the absence of CO2. Cells
were visualized the following day and quantified (minimum of 50 cells per trial)
for the presence or absence of staining.
Radiation response. Passage 4 KSR1⫺/⫺ or KSR1⫹/⫹ MEFs (1 ⫻ 106) were
plated in complete media 24 h prior to analysis. Cells were irradiated with 8 Gy
and then incubated at 37°C for the indicated times prior to lysis and Western blot
analysis.
Transformation assays. MEFs stably expressing RasV12 and KSR1 or control
vectors were seeded in 0.32% Nobel agar at 1 ⫻ 104 cells per 35-mm dish to assess
anchorage-independent growth or seeded at 1 ⫻ 105 cells per 10-cm dish to assess
loss of contact inhibition. Colonies were counted, photomicrographs were taken, and
dishes were stained with Wright-Giemsa 14 to 28 days after seeding.
In situ ERK activation assay. Cells were seeded at 1.5 ⫻ 104 cells/well in a
96-well plate 24 h prior to analysis and subjected to an in situ plate assay using
a Li-Cor Odyssey infrared imaging system to quantify ERK activation. Cells at
70% confluence were deprived of serum for 4 h and treated with 25 ng/ml
platelet-derived growth factor (PDGF) in Dulbecco’s modified Eagle’s medium–1%
bovine serum albumin for 5 min. Anti-phospho-ERK1/2 (Cell Signaling) (1:100)
and anti-ERK1 (Santa Cruz, 1:100) primary antibodies and anti-mouse Alexa
Fluor 680-conjugated (Molecular Probes) (1:100) and anti-rabbit IRDye800conjugated (Rockland) (1:100) secondary antibodies were used to detect and
quantify phosphorylated and total ERK protein levels.
Lysate preparation and Western blotting. Cells were treated with trypsin and
pelleted. Pellets were washed twice with PBS and frozen at ⫺80°C. Frozen
pellets were sonicated (2 ⫻ 7 s) in ice-cold lysis buffer (50 mM HEPES [pH
7.5], 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 0.1% Tween 20, 1 mM
phenylmethylsulfonyl fluoride, 0.4 U/ml aprotinin, 1 mM NaF, 10 mM ␤-glycerophosphate, 0.1 mM sodium orthovanadate). Following sedimentation of
undissolved cellular material by centrifugation (Sorvall Biofuge) (4°C, 7 min,
14,000 rpm), lysates were assayed for protein concentration by use of a DC
protein assay (Bio-Rad). A 50-g volume of total protein was loaded per well,
and lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and Western blotting. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. Western blot analysis was developed using the following
primary and secondary antibodies (antibodies were from Santa Cruz unless
otherwise noted): anti-p53 (Ab-7; Calbiochem) (1:2,500), anti-phospho-p53
(Ser18) (Cell Signaling) (1:1,000), anti-p19ARF (Abcam) (1:400), antip15INK4b (Biosource) (1:400), anti-MEK1/2 (Cell Signaling) (1:1,000), antiphosphoMEK (Cell Signaling) (1:1,000), anti-phospho-ERK1/2 (Cell Signaling) (1:1,000), anti-Ras (Oncogene) (1:1,000), anti-PML (Upstate) (1:800), or
antitubulin (Sigma) (1:1,000). Anti-mouse, anti-rabbit, anti-sheep, and antigoat secondary antibodies conjugated to Alexa Fluor 680 (Molecular Probes)
(1:3,000) and IRDye800 (Rockland) (1:3,000) were used to probe primary
antibodies. Protein bands were detected and quantified on a Li-Cor Odyssey
infrared imaging system.

RESULTS
KSR1 is necessary for RasV12-induced senescence. Expression of oncogenic Ras causes cellular senescence in primary
MEFs via activation of the Raf/MEK/ERK cascade (9, 20, 41,
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stabilizes p53 expression and can regulate whether p53 activation produces senescence or apoptosis (20).
Kinase Suppressor of Ras 1 (KSR1) is a molecular scaffold
for the Raf/MEK/ERK cascade (37, 46, 49). KSR1 expression
regulates the intensity and duration of growth factor-induced
ERK activation to modulate a cell’s proliferative, oncogenic,
and adipogenic potential (36, 37, 55). Importantly, immortalized KSR1⫺/⫺ MEFs are resistant to oncogenic transformation
by RasV12, which can be rescued by ectopic expression of
KSR1 (37). Deletion of KSR1 blocks RasV12-induced ERK
activation but not activation of other Ras effector pathways,
indicating that KSR1-scaffolded ERK activation is necessary
for RasV12-induced transformation (37).
Given the necessity of KSR1 expression in RasV12-induced
transformation in immortalized MEFs, we assessed whether
KSR1 was necessary for RasV12-induced senescence in primary
MEFs. RasV12-induced senescence and replicative senescence
are phenotypically similar and require many of the same pathways. Therefore, we also assessed whether KSR1 could play a
role in cellular immortalization. We show that KSR1 is necessary for RasV12-induced senescence and that its deletion accelerates 3T9-mediated immortalization of primary MEFs.
KSR1⫺/⫺ MEFs were resistant to RasV12-induced senescence
and instead showed increased proliferation. Furthermore,
RasV12 failed to induce p53, p19ARF, p16INK4a, and p15INK4b
expression in primary KSR1⫺/⫺ MEFs. Reintroduction of
wild-type KSR1, but not a mutated KSR1 construct unable to
bind activated ERK, restored RasV12-induced senescence. On
continuous culture, deletion of KSR1 accelerated spontaneous
immortalization and increased the number of primary cultures
escaping replicative crisis. Coupled to the observation that
immortalized KSR1⫺/⫺ MEFs are resistant to RasV12-induced
transformation (37, 42), these data demonstrate that KSR1scaffolded ERK activity is necessary for RasV12-induced and
replicative senescence and for transformation.
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59, 76). KSR1 is a molecular scaffold of the Raf/MEK/ERK
cascade (37, 46, 49). Previous data indicated that KSR1 was
necessary for RasV12 to transform immortalized MEFs (37).
To assess whether KSR1 was required for RasV12-induced
senescence, early-passage KSR1⫺/⫺ and KSR1⫹/⫹ MEFs were
infected with a recombinant retrovirus expressing RasV12 or
with control virus and were assessed for characteristics of senescence. As expected, expression of RasV12 in KSR1⫹/⫹
MEFs induced cellular senescence. KSR1⫹/⫹ MEFs expressing

RasV12 failed to proliferate in culture (Fig. 1A), had a characteristic enlarged and flattened morphology (Fig. 1B), and demonstrated SA ␤-galactosidase activity (Fig. 1C). In contrast,
RasV12 did not induce growth arrest in KSR1⫺/⫺ MEFs but
instead induced proliferation. KSR1⫺/⫺ MEFs expressing
RasV12 proliferated at a much higher rate than control MEFs
in culture (Fig. 1A), were morphologically similar to control
fibroblasts (Fig. 1B), and lacked ␤-galactosidase activity (Fig.
1C). Previous data demonstrate that, although Ras activa-
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FIG. 1. KSR1 is necessary for RasV12-induced senescence in primary MEFs. (A) Passage 4 to 6 KSR1⫺/⫺ (squares) or KSR1⫹/⫹ (triangles)
MEFs expressing RasV12 (closed) or control (open) vectors were seeded at 5 ⫻ 104 cells per 35-mm dish. Separate duplicate dishes were assessed
for cell number every 48 h on a Beckman Coulter Counter. Data are expressed as means ⫾ standard deviations (SD) of three independent
experiments. (B) Photomicrographs (10⫻) of cells analyzed in panel A. (C) Photomicrographs (10⫻) of RasV12-expressing cells analyzed in panel
A and stained to visualize SA ␤-galactosidase activity as described in Materials and Methods. (D) Western blot analysis of whole-cell extracts
prepared from passage 4 to 6 KSR1⫺/⫺ and KSR1⫹/⫹ MEFs expressing RasV12 or control vector. Lysates were probed with the indicated antibodies
to detect induction and activation of each protein by RasV12. Actin and tubulin were used to demonstrate equal loading of each sample, and Ras
and KSR1 expression results are shown as controls. Data are representative of four independent experiments.
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FIG. 2. Induction of p53 activity by ␥ irradiation is independent of
KSR1. Passage 4 KSR1⫺/⫺ and KSR1⫹/⫹ MEFs were irradiated with 8
Gy, and whole-cell extracts were prepared at the indicated times after
radiation exposure. Lysates were probed with the indicated antibodies
to assess the induction of p53 activity. Actin was used to demonstrate
equal loading of each sample. Data are representative of two independent experiments.

induction of p53, PML, p21CIP1, p19ARF, DMP1, p16INK4a, and
p15INK4b, lowered basal levels of p19ARF, and restored the responsiveness of p19ARF to RasV12 (Fig. 3D).
RasV12-induced senescence requires KSR1-ERK interaction. While the site(s) of association between KSR1 and Raf
has not been well defined, sites of interaction for MEK and
activated ERK have been identified on KSR1. Furthermore,
site-directed mutagenesis of KSR1 can abrogate the KSR1MEK or KSR1-ERK interactions. Mutated forms of KSR1 can
be used to assess the relative role each KSR1-effector interaction plays in KSR1-mediated biological functions (5, 19, 31, 47,
65, 75). To assess the effects of KSR1-scaffolded ERK activation on RasV12-induced senescence, mutated KSR1 constructs
lacking the ability to interact with MEK (KSR1.C809Y) (47,
65, 75) or activated ERK (KSR1.FSFP/AAAP) (19, 31) were
introduced into KSR1⫺/⫺ MEFs expressing RasV12 or control
vector by use of the bicistronic retroviral system described
above. Introduction of these mutated KSR1 constructs into
RasV12-expressing KSR1⫺/⫺ MEFs demonstrated that the
KSR1-ERK interaction, but not the KSR1-MEK interaction,
was necessary for RasV12 to induce senescence. KSR1.C809Y,
a mutated KSR1 construct unable to bind MEK (47, 65, 75),
was able to induce growth arrest and SA ␤-galactosidase activity as well as wild-type KSR1 (Fig. 3A to C). In contrast,
KSR1.FSFP/AAAP, a mutated form of KSR1 unable to bind
activated ERK (19, 31), did not arrest growth and showed a
diminished ability to promote RasV12-induced SA ␤-galactosidase activity. KSR1.FSFP/AAAP cells expressing RasV12 did
not, however, proliferate at rates as high as control (GFP) cells
expressing RasV12, indicating that there may be a reduction in
proliferative signals from RasV12 in the absence of an intact
KSR1-ERK interaction (Fig. 3A-C).
Similarly to KSR1⫺/⫺ MEFs expressing wild-type KSR1,
RasV12 induced expression of p53, p19ARF, DMP1, p16INK4a,
and p15INK4b in KSR1⫺/⫺ MEFs expressing KSR1.C809Y,
providing further evidence that the KSR1-MEK interaction
is dispensable during RasV12-induced senescence. In contrast, RasV12 induced expression of p53 and p19ARF, but
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tion of the Raf/MEK/ERK effector pathway is defective in
immortalized KSR1⫺/⫺ MEFs, activation of other Ras effector pathways is unaltered (37). These data indicate that
the KSR1-scaffolded Raf/MEK/ERK effector pathway is
critical in determining whether RasV12 induces senescence
or cell proliferation in primary MEFs.
RasV12 is reported to induce senescence in primary cells via
the p19ARF/p53 and INK4/Rb pathways (1, 13, 15, 20, 21, 30,
41, 43, 50, 52, 57, 59, 64, 76). To understand which of these
pathways failed to be induced by RasV12 in KSR1⫺/⫺ MEFs,
Western blotting was performed for p53, PML, p21CIP1,
p19ARF, DMP1, p16INK4a, and p15INK4b in KSR1⫺/⫺ and
KSR1⫹/⫹ MEFs expressing RasV12 and in control cells. Western blot analyses for Ras, KSR1, tubulin, and actin were performed as controls. Retroviral introduction of RasV12 induced
the phosphorylation of MEK and ERK and the expression of
p53, PML, p21CIP1, p19ARF, DMP1, p16INK4a, and p15INK4b in
KSR1⫹/⫹ MEFs. In contrast, expression of RasV12 failed to
stimulate the phosphorylation of MEK or ERK or to induce
p53, PML, p21CIP1, p19ARF, DMP1, p16INK4a, or p15INK4b
expression in KSR1⫺/⫺ MEFs (Fig. 1D). Interestingly, although p19ARF was not induced by RasV12 in KSR1⫺/⫺ MEFs,
we routinely saw a two- to fourfold elevation in basal p19ARF
in KSR1⫺/⫺ MEFs compared to KSR1⫹/⫹ MEF results (Fig.
1D, vector controls). Elevated p19ARF levels can indicate a
lack of p53 function (34, 53). To assess whether KSR1⫺/⫺
MEFs lacked functional p53, p53 induction and p53 activity in
response to ␥ irradiation were assessed in early-passage
KSR1⫺/⫺ and KSR1⫹/⫹ MEFs.
p53 was induced rapidly and transiently in both KSR1⫺/⫺
and KSR1⫹/⫹ MEFs (Fig. 2). To assess whether the induced
p53 was transcriptionally active, Western blot analysis was performed for two transcriptional targets of p53, mdm2 and
p21CIP1 (2, 18, 73). Both mdm2 and p21CIP1 were induced 2 to
4 h after exposure of KSR1⫺/⫺ and KSR1⫹/⫹ MEFs to ␥
irradiation (Fig. 2), indicating that p53 can be activated by
ATM following DNA damage in KSR1⫺/⫺ MEFs. These data
demonstrate that KSR1⫺/⫺ MEFs express functional p53 but
that p53 activity cannot be induced by activated RasV12 to
trigger cellular senescence in the absence of KSR1.
To address whether KSR1 was necessary for RasV12 to cause
senescence in primary MEFs, KSR1 was reintroduced into
KSR1⫺/⫺ MEFs by use of a bicistronic retrovirus encoding
KSR1 and green fluorescent protein (GFP). The level of KSR1
expression has significant effects on RasV12-mediated transformation and Raf/MEK/ERK signaling (37). Reintroduction of
physiologic levels of KSR1 rescues RasV12-mediated transformation and ERK activation, whereas supraphysiologic levels of
KSR1 further enhance transformation and ERK activation to
a maximum at 14 times the level of KSR1 expression found in
KSR1⫹/⫹ MEFs (37). Higher levels of KSR1 expression inhibit
transformation and ERK activation, consistent with the role of
KSR1 as a molecular scaffold (8, 37). Therefore, cells expressing
low levels of ectopic KSR1 were selected by flow cytometry to
ensure that physiologically relevant levels of KSR1 expression,
shown previously not to affect the rate of proliferation, were used
in our analysis (Fig. 3D). Reintroduction of KSR1 restored
RasV12-induced senescence in KSR1⫺/⫺ MEFs (Fig. 3), as assessed by proliferative arrest (Fig. 3A) and SA ␤-galactosidase
activity (Fig. 3B and C). KSR1 also restored RasV12-mediated
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FIG. 3. The KSR1-ERK interaction is required, but the KSR1-MEK interaction is dispensable, for RasV12-induced senescence in KSR1⫺/⫺
MEFs. Passage 5 KSR1⫺/⫺ MEFs were infected with recombinant retrovirus encoding KSR1, a KSR1 construct unable to bind activated ERK
(KSR1.FSFP/AAAP) or a KSR1 construct unable to bind MEK (KSR1.C809Y), and RasV12 or a control virus. Low levels of KSR1 expression were
selected by FACS analysis for levels of GFP expression previously shown to correlate with 1⫻ to 5⫻ KSR1⫹/⫹ levels. (A) Proliferation in passage
5 KSR1⫺/⫺ MEFs expressing the indicated KSR1 construct and RasV12 (closed squares) or control (open diamonds) vectors. Separate duplicate
dishes were assessed for cell number every 48 h on a Beckman Coulter Counter. Data are expressed as means ⫾ SD of three independent
experiments. (B) Photomicrographs (10⫻) of cells analyzed in panel A and stained to visualize SA ␤-galactosidase activity as described in Materials
and Methods. (C) Quantification of cells analyzed in panel A and stained to visualize SA ␤-galactosidase (␤-Gal) activity as described in Materials
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FIG. 4. The KSR1-ERK interaction is required, but the KSR1MEK interaction is dispensable, for RasV12-induced transformation
and PDGF-induced ERK activation in immortal KSR1⫺/⫺ MEFs. Immortal KSR1⫺/⫺ MEFs were infected with recombinant retrovirus
encoding KSR1, KSR1.FSFP/AAAP, or KSR1.C809Y and RasV12 or a
control virus. Low levels of KSR1 expression were selected by FACS
analysis for levels of GFP expression previously shown to correlate
with 1⫻ to 5⫻ KSR1⫹/⫹ levels. (A) Cells were assessed for transformation by growth on soft agar as described in Materials and Methods.
Data are expressed as means ⫾ SD from two independent experiments. (B) Triplicate wells expressing the indicated KSR1 construct
were treated with 25 ng of PDGF/ml for the indicated times, and
ERK1/2 phosphorylation levels were determined by in-cell Western
blotting for ERK1 and pERK1/2 with a Li-Cor Odyssey system. Data
are expressed as ratios of pERK1/2 to ERK1. Data are expressed as
means ⫾ SD.

and Methods. Separate triplicate dishes were quantified for each cell line, with a minimum of 50 cells quantified per well. Data are expressed as
mean percentages of cells ⫾ SD from three independent experiments. (D) Western blot analysis of whole-cell extracts prepared from passage 5
KSR1⫺/⫺ MEFs expressing the indicated KSR1 constructs and RasV12 or control vector. Lysates were probed with the indicated antibodies to
detect induction and activation of each protein by RasV12. Actin and tubulin were used to demonstrate equal loading of each sample, and Ras and
KSR1 expression results are shown as controls. Data are representative of four independent experiments.
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not p16INK4a or p15INK4b, in KSR1⫺/⫺ MEFs expressing
KSR1.FSFP/AAAP (Fig. 3D). Induction of p21CIP1 also required the interaction of KSR1 with ERK (Fig. 3D). This
observation appears consistent with the p53-independent
induction of p21CIP1 by Raf (72). RasV12-induced MEK
phosphorylation is rescued by the expression of either
KSR1.FSFP/AAAP or KSR1.C809Y. However, ERK activation is not rescued by KSR1.FSFP/AAAP (Fig. 3D). These
data indicate that KSR1 is necessary for RasV12-induced
senescence and that the effects of KSR1 require its interaction with activated ERK.
The effects of the FSFP/AAAP and C809Y mutations in
KSR1 on RasV12-induced senescence led us to assess
whether the KSR1-MEK or KSR1-ERK interactions were
required for RasV12-mediated transformation in immortal
MEFs. As observed previously (37), KSR1 expression was
necessary for RasV12-induced transformation in immortalized KSR1⫺/⫺ MEFs (Fig. 4A). The KSR1-MEK interaction
was dispensable for transformation, as KSR1.C809Y cells
expressing RasV12 showed enhanced colony formation in
comparison to wild-type KSR1 cells. KSR1⫺/⫺ MEFs expressing KSR1.FSFP/AAAP were also transformed. However, disruption of the interaction of KSR1 with activated
ERK diminished the transforming potential of RasV12, as
these cells showed only 30% of the colonies seen with cells
expressing wild-type KSR1 (Fig. 4A).
Given the contrasting results observed upon disruption of
KSR1-MEK and KSR1-ERK interactions, we sought to further understand the signaling properties of cells expressing
these mutated KSR1 constructs. We examined the kinetics
of PDGF-induced ERK activation in immortal KSR1⫺/⫺
MEFs expressing KSR1, KSR1.C809Y, or KSR1.FSFP/AAAP
(Fig. 4B). Cells expressing wild-type KSR1 showed rapid induction of ERK activation at 5 min, followed by a lower level
of sustained signaling out to 2 h. When the KSR1-MEK interaction was disrupted by the C809Y mutation in KSR1, there
was no decrease in peak ERK activation, and ERK phosphorylation was sustained in comparison to that of cells expressing
wild-type KSR1. In contrast, disruption of the interaction of
KSR1 with activated ERK (FSFP/AAAP) blunted peak ERK
activation (Fig. 4B). These results suggest that the role of
KSR1 is not only to facilitate activation of the Raf/MEK/ERK
cascade but that KSR1 is also required to maintain the fidelity
of RasV12-induced ERK activity necessary for senescence (Fig.
3) and transformation (Fig. 4).
KSR1 enhances the cellular response to activated MEK.
Whereas previous studies have shown a role for KSR1 in facilitating the activation of Raf by Ras (45) and MEK by Raf
(48, 49, 56), our data suggest that KSR1 promotes signal propagation downstream of MEK. To explore the role of KSR1 in
facilitating signaling downstream of MEK, we examined cell
transformation (Fig. 5) and senescence (Fig. 6) induced by a
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constitutively active MEK construct (MEKEE) containing glutamic acid substitutions for Ser218/222 (7, 12, 41, 44) in the
presence and absence of KSR1. To study transformation, immortal KSR1⫺/⫺ and KSR1⫹/⫹ MEFs were infected with retroviruses encoding RasV12 or MEKEE and were assessed for
ERK activation and transformation by examining anchorageindependent growth and loss of contact inhibition (Fig. 5). In
immortal KSR1⫹/⫹ MEFs, RasV12 or MEKEE expression in-

creased ERK activation (Fig. 5A), caused colony formation on
soft agar (Fig. 5B), and induced focus formation (Fig. 5C). As
reported previously (37), RasV12 was unable to increase ERK
activation or transform immortal KSR1⫺/⫺ MEFs. MEKEE
expression in KSR1⫺/⫺ MEFs led to an intermediate phenotype. While there was no increase in ERK activation (Fig. 5A),
the cells exhibited anchorage independence (Fig. 5B) and a
loss of contact inhibition (Fig. 5C), although to a much lesser
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FIG. 5. KSR1 is not required for, but enhances, MEKEE-induced transformation in immortal KSR1⫺/⫺ MEFs. Immortal KSR1⫺/⫺ and
KSR1⫹/⫹ MEFs were infected with recombinant retrovirus encoding MEKEE, RasV12, or a control virus. (A) Western blot analysis of whole-cell
extracts prepared from immortal KSR1⫺/⫺ and KSR1⫹/⫹ MEFs expressing MEKEE, RasV12, or control vector. Lysates were probed with
antibodies against pERK1/2 and ERK1/2 to detect activation of ERK by MEKEE or RasV12. Actin was used to demonstrate equal loading of each
sample, and expression blots of Ras, MEK1, and KSR1 are shown as controls. For MEK1 blots, low exposures are shown to indicate cells that have
received the MEKEE transgene and not expression of endogenous MEK1. Data are representative of four independent experiments. (B and C)
Cells were assessed for transformation by growth on soft agar (B) and focus formation (C) as described in Materials and Methods. Data are
expressed as means ⫾ SD from two independent experiments.
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extent than seen in KSR1⫹/⫹ MEFs. When grown on a semisolid medium, KSR1⫺/⫺ MEFs expressing MEKEE formed
approximately 25% of the colonies seen in KSR1⫹/⫹ MEFs
and when contact inhibition was assessed required 5 to 6 weeks

to form colonies equal in size to those observed 10 days after
plating KSR1⫹/⫹ MEFs expressing MEKEE.
MEKEE also caused cellular senescence in primary
KSR1⫹/⫹ MEFs (Fig. 6). However, as observed with trans-
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FIG. 6. KSR1 is necessary for MEKEE-induced senescence in primary MEFs. (A) Western blot analysis of whole-cell extracts prepared from passage
4 to 6 KSR1⫺/⫺ and KSR1⫹/⫹ MEFs expressing MEKEE, RasV12, or control vector. Lysates were probed with the indicated antibodies to detect induction
and activation of each protein by MEKEE or RasV12. Actin was used to demonstrate equal loading of each sample, and expression blots of Ras, MEK1,
and KSR1 are shown as controls. For MEK1 blots, low exposures are shown to indicate cells that have received the MEKEE transgene and not expression
of endogenous MEK1. (B) Passage 4 to 6 KSR1⫺/⫺ (squares) or KSR1⫹/⫹ (triangles) MEFs expressing RasV12 (closed), MEKEE (gray), or control
(open) vectors were seeded at 1 ⫻ 104 cells per well in a 24-well plate. Separate duplicate dishes were assessed for cell number every 72 h by trypan blue
exclusion. Data are expressed as means ⫾ SD from two independent experiments. (C) Photomicrographs (10⫻) of cells analyzed in panel A and stained
to visualize SA ␤-galactosidase activity as described in Materials and Methods. (D) Quantification of cells analyzed in panel A and stained to visualize
SA ␤-galactosidase activity as described in Materials and Methods. Separate triplicate wells were quantified for each cell line, with a minimum of 100 cells
quantified per well. Data are expressed as means ⫾ SD from four independent experiments.
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FIG. 7. Loss of KSR1 allows for early immortalization of primary
mouse embryo fibroblasts. (A) Passage 3 KSR1⫺/⫺ and KSR1⫹/⫹
MEFs were passaged by a 3T9 protocol until immortalized populations
were obtained. Data are means ⫾ SD of four embryos of each genotype. (B) At passages 5, 10, 15, and 18, 2 ⫻ 104 MEFs were plated in
35-mm dishes and counted either daily or every 72 h to assess lowdensity growth. Data are means ⫾ SD of three embryos of each
genotype. (C) KSR1⫹/⫹, KSR1⫹/⫺, and KSR1⫺/⫺ MEFs at passage 9
were seeded at 2 ⫻ 104 cells/60-mm dish and fed twice weekly for 4
weeks. Colonies consisting of at least 16 cells that arose from MEFs of
each genotype were counted. Data are expressed as means ⫾ SD from
two embryos of each genotype.

proliferation compared to KSR1⫹/⫹ MEFs, with similar lag
times of 6 to 8 days before the enhanced cell proliferation was
observed (Fig. 7B). These data indicate that compared to
KSR1⫹/⫹ MEFs, KSR1⫺/⫺ MEFs are predisposed to spontaneous immortalization. Furthermore, these data show that im-
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formation, MEKEE caused an intermediate phenotype in
primary KSR1⫺/⫺ MEFs. Expression of MEKEE caused a
modest increase in ERK activation but failed to induce
expression of p53 or the INK4 proteins (Fig. 6A). Furthermore, primary KSR1⫺/⫺ MEFs expressing MEKEE did not
undergo growth arrest, instead proliferating as well as or
better than control cells (Fig. 6B). When stained for ␤-galactosidase activity, primary KSR1⫺/⫺ MEFs expressing
MEKEE consistently showed 35 to 40% positive staining
(versus 75 to 80% for KSR1⫹/⫹ MEFs expressing MEKEE
or RasV12) (Fig. 6B and C). These data demonstrate that,
similarly to its effects on transformation (Fig. 5), MEKEE
cannot fully promote senescence in the absence of KSR1.
These data suggest that KSR1 promotes not only the activation of MEK (48) but also transmission of the activated
MEK signal to its downstream target.
Deletion of KSR1 enhances spontaneous immortalization of
fibroblasts. RasV12-induced senescence and replicative senescence are both mediated, in part, by activation of the p19ARF/
p53 and p16INK4a/Rb pathways (50, 59). Since KSR1⫺/⫺ MEFs
were defective in RasV12-mediated induction of p53, p16INK4a,
and p15INK4b and in RasV12-induced senescence, we assessed
whether KSR1⫺/⫺ MEFs would exhibit a propensity to escape
replicative senescence. To assess whether KSR was involved in
spontaneous immortalization of fibroblasts, KSR1⫺/⫺ and
KSR1⫹/⫹ MEFs were passaged by a 3T9 protocol (10, 67) until
either cell death or spontaneous immortalization occurred.
KSR1⫹/⫹ MEFs showed a rapid decline in cellular proliferation beyond passage 5 and exhibited marked amounts of cell
death around passages 15 to 20, consistent with previous reports (Fig. 7A) (42). KSR1⫺/⫺ MEFs also exhibited a rapid
decline in cellular proliferation after passage 5 and were similar to KSR1⫹/⫹ MEFs in both appearance and number until
approximately passage 15. At this point, KSR1⫺/⫺ MEFs
showed a brief proliferative burst (2 to 4 passages) followed by a
second period of growth arrest which lasted 5 to 7 more passages.
Between passages 23 and 26, KSR1⫺/⫺ MEFs began to proliferate, and 10 out of 11 (91%) KSR1⫺/⫺ cultures had immortalized
by passage 30. In contrast, KSR1⫹/⫹ MEFs showed no signs of
proliferation until passage 35 or later, after which 4 out of 11
(36%) KSR1⫹/⫹ cultures began to proliferate and eventually became immortal (Fig. 7A).
To assess the growth characteristics of KSR1⫺/⫺ and
KSR1⫹/⫹ MEFs during the immortalization process, cells from
three independent KSR1⫺/⫺ and KSR1⫹/⫹ cultures at passages 5, 10, 15, and 18 were assessed for proliferation rate at
low density (Fig. 7B). Consistent with previously published
data, early-passage KSR1⫺/⫺ MEFs proliferated at a slightly
slower rate than KSR1⫹/⫹ MEFs (42). However, we did not
see the marked differences in proliferative rate between
KSR1⫺/⫺ and KSR1⫹/⫹ MEFs observed by Lozano et al. (42).
The discrepancy might be explained by differences in passage
number between the two experiments (see Discussion). When
plated at passage 10, there was no difference in proliferative
rate between KSR1⫺/⫺ and KSR1⫹/⫹ MEFs for the first 6 days
of the experiment. We observed increased cell proliferation in
KSR1⫺/⫺ MEFs between days 7 and 10 of this experiment,
however, indicating that immortalized cells may already exist
within the KSR1⫺/⫺ cultures at this time. KSR1⫺/⫺ MEFs
plated at passages 15 and 18 also showed enhanced cellular

MOL. CELL. BIOL.

VOL. 26, 2006

KSR1 IS A MODIFIER OF SENESCENCE

DISCUSSION
Here we show that the molecular scaffold KSR1 is a potent modifier of replicative senescence. Deletion of KSR1
enhanced spontaneous immortalization of primary MEFs,
increasing the frequency of immortalization and decreasing
the time necessary for primary cultures to escape from replicative crisis. KSR1 was also required for senescence induced by activated RasV12. In the absence of KSR1, RasV12
stimulated proliferation instead of senescence. Expression
of mutated forms of KSR1 revealed that the KSR1-ERK
interaction was necessary for RasV12 to cause growth arrest
of primary cells. Though the interaction of KSR1 with MEK
was not required for RasV12-induced senescence, KSR1 expression amplified the effect of an activated MEK construct
on senescence in primary MEFs and transformation in immortal MEFs. Signaling from RasV12 to both the p19ARF/
p53 and INK4/Rb pathways was defective in KSR1⫺/⫺
MEFs, which likely underlies both the escape from RasV12induced senescence and the enhanced spontaneous immortalization observed in KSR1⫺/⫺ MEFs.
RasV12 causes senescence by engaging the p19ARF/p53 and
p16INK4a/Rb pathways, although the relative contributions of
these pathways differ between mouse and human cells. p19ARF
plays a more important role in senescence in mouse cells,
whereas p16INK4a is more important in senescence in human
cells (9, 28, 29, 50, 58, 59, 69). In murine fibroblasts, ablation of
these pathways allows RasV12 to enhance cell proliferation
instead of growth arrest (13, 34, 50, 52, 57, 59). KSR1 was
necessary for RasV12 to increase phosphorylation of ERK and
for the expression of p53, PML, p19ARF, DMP1, p16INK4a, and
p15INK4b (Fig. 1D). In the absence of these antiproliferative
signals, RasV12 caused proliferation instead of growth arrest in
primary MEFs. RasV12 signals to the proliferative machinery
via multiple effector pathways, including the PI 3⬘ kinase/Akt,
RalGEF/Ral, and Raf/MEK/ERK cascades (23, 24). In primary murine cultures, activation of the Raf/MEK/ERK cascade, but not the other effector pathways, engages the p53/
ARF and INK4/Rb pathways, causing senescence instead of
proliferation (41, 76). Deletion of the molecular scaffold KSR1
blocks the ability of RasV12 to signal through the Raf/MEK/
ERK effector pathway to these antiproliferative pathways (Fig.
1) but leaves signaling to other Ras effectors intact (37). Thus,
in primary MEFs lacking KSR1, RasV12 signaling through the
Raf/MEK/ERK signaling cassette to the antiproliferative p53/
ARF and INK4/Rb pathways is limited, allowing proliferation
instead of growth arrest.
The interaction of KSR1 with activated ERK appears nec-

essary for RasV12-induced senescence (Fig. 5) and for maximal
RasV12-induced transformation (Fig. 6). While the activation
of MEK is intact in cells expressing KSR1.FSFP/AAAP, maximal ERK activation is lost; indicating that the interaction of
KSR1 with activated ERK is necessary for signal fidelity. Interestingly, MEK activation is increased in KSR1⫺/⫺ MEFs
expressing KSR1.FSFP/AAAP, raising the possibility that a
molecular brake on Raf activity is lost by disruption of KSR1
interaction with ERK. Dougherty et al. (17) recently reported
feedback inhibition of Raf by ERK. Since MEK phosphorylation (and therefore Raf activity) is increased in KSR1.FSFP/
AAAP cells, these data suggest that KSR1 may be required not
only to facilitate but also to moderate signaling through the
Raf/MEK/ERK cascade.
To assess whether KSR1 facilitates the activation of ERK by
MEK, we examined the role of MEKEE (activated MEK) in
senescence and transformation in KSR1⫺/⫺ MEFs. We observed that the introduction of MEKEE into KSR1⫺/⫺ MEFs
yields a phenotype intermediate between those observed after
introduction of RasV12 in KSR1⫹/⫹ and in KSR1⫺/⫺ MEFs.
While MEKEE transforms KSR1⫺/⫺ MEFs, these cells have
only 20% of the transformed foci compared to the results seen
with KSR1⫹/⫹ MEFs expressing MEKEE (Fig. 5). Additionally, while MEKEE does not cause growth arrest in primary
KSR1⫺/⫺ MEFs, there are an increased number of ␤-galactosidase-positive cells (Fig. 6). These data show that activated
MEK is not sufficient to compensate for the lack of KSR1,
indicating that KSR1 facilitates MEK function. These data
reveal a previously unappreciated role of KSR1 in the maintenance of the fidelity of signaling from MEK to ERK. Furthermore, in conjunction with the intermediate phenotype
seen with disruption of the interaction between KSR1 and
activated ERK (FSFP/AAAP), these data show that specific
scaffold-effector interactions are necessary to maintain signaling fidelity and assure the correct cellular response to pathway
activation.
Expression of KSR1.C809Y, a form of KSR1 that cannot
bind MEK (47, 65), still allowed RasV12 to induce MEK and
ERK activation, senescence in primary MEFs, and transformation in immortal MEFs (Fig. 3 and 4). The C809Y mutation
is orthologous to a loss-of-function mutation in KSR1 detected
in genetic screenings using Caenorhabditis elegans (66). While
others have shown that this mutation precludes MEK activation (56), we found that MEK and ERK phosphorylation are
enhanced (Fig. 3). These differences may be due, in part, to
differences in experimental design or in signaling between
mammalian and invertebrate systems. The KSR1-MEK interaction is necessary for many KSR1 functions, including its
ability to translocate to the nucleus (5) and promote PC12 cell
differentiation (47). In these studies, KSR1.C809Y exhibited a
clear loss of function, which validates the biological importance of the KSR1-MEK interaction. Others have also reported a lack of biological activity for KSR1.C809Y (32, 65),
but these studies used a KSR1 overexpression system where
the readout was pathway inactivation via combinatorial inhibition. We also found a lack of combinatorial inhibition by use of
the KSR1.C809Y construct (unpublished data). However, loss
of the KSR1-MEK interaction enhances pathway activity at
physiologic levels (Fig. 3 and 4). The disruption of KSR1’s
interaction with MEK may impair function in certain biological

Downloaded from http://mcb.asm.org/ on January 10, 2014 by Washington University in St. Louis

mortalized KSR1⫺/⫺ MEFs exist in cultured cell populations
as early as passage 10.
The effect of KSR1 on the potential of MEFs to immortalize
was tested further by plating KSR1⫹/⫹, KSR1⫹/⫺, and
KSR1⫺/⫺ MEFs at passage 9 at low density and allowing the
cells to grow for 4 weeks. Analysis of the colonies formed from
cells of each genotype (Fig. 7C) revealed that twice as many
colonies arose from KSR1⫺/⫺ MEFs at passage 9 as from
KSR1⫹/⫹ MEFs. An intermediate number of colonies arose
from MEFs heterozygous for KSR1. These data suggest that
KSR1 serves as a barrier against immortalization.
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KSR1 expression moderates ERK activity to affect a cell fate
(Fig. 1 and references 36 and 37), with the biologic outcome
dependent upon cellular context and the overall activation of
downstream effectors.
These data suggest that, in some circumstances, escape from
premature senescence may not be an inextricable step toward
cell transformation and tumorigenesis. Senescent fibroblasts,
when seeded as tumor stroma, can promote epithelial cell
transformation in situ and tumorigenesis in vivo (9, 38). Senescent fibroblasts secrete both soluble factors and extracellular matrices that promote the growth of premalignant, but not
normal, epithelial cells. Furthermore, this ability to promote
tumorigenesis occurs irrespective of whether the senescence
was induced by replicative exhaustion or oncogenic RasV12 (9,
38). Since KSR1⫺/⫺ MEFs are resistant to RasV12-induced
senescence (Fig. 1) and less susceptible to replicative senescence (Fig. 7), it is conceivable that targeted disruption of
KSR1 function could not only block the transforming capacity
of cancer cells but also diminish the ability of stromal cells to
promote tumorigenesis. Xing et al. (74) recently reported that
treatment of EGFR-A431 or PANC-1 cells with antisense oligonucleotides against KSR1 blocked their proliferation in situ
and in immunodeficient mice. Furthermore, the authors
showed that treatment of mice with antisense oligonucleotides
against KSR1 reduced the volume of established PANC-1 tumors. Based on these findings, Xing et al. (74) proposed phase
I clinical trials to assess inactivation of KSR1 in pancreatic
cancers. Our data suggest that the targeted disruption of KSR1
by use of antisense oligonucleotides could have therapeutic
efficacy against RasV12-driven tumors at multiple levels. Within
the tumor cells, reduction of KSR1 expression should reduce
proliferative signals. In surrounding tissues, reduction of KSR1
expression could decrease the formation of senescent cells,
thereby reducing the tumor-promoting properties of the surrounding stroma.
Based on these data, we propose that KSR1 expression is
a barrier that cells must overcome during immortalization.
While spontaneous deletion of KSR1 to escape senescence has
not been reported, disruption of KSR1-regulated pathways
would have the same effect. KSR1 allows RasV12 to engage the
antiproliferative p19ARF/p53 and INK4/Rb pathways. Spontaneous mutations within these pathways promote immortalization (25, 34). Furthermore, genetic inactivation of either of
these pathways blocks both RasV12-induced and replicative
senescence (1, 10, 13, 20, 26, 30, 34, 50, 52, 57–59). The inability of RasV12 to induce senescence in KSR1⫺/⫺ MEFs, combined with the enhanced propensity of KSR1⫺/⫺ MEFs to
immortalize, indicates that KSR1 is a potent modifier of replicative potential.
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contexts (5, 47, 66) but increase function in others (Fig. 3 and
4) due to its ability to moderate signal output through the
Raf/MEK/ERK signaling cassette. Elevating KSR1 expression
promoted maximal activation of the Raf/MEK/ERK cascade,
cell proliferation, and RasV12-induced transformation (37).
However, ERK activation must be constrained within a narrow
range by physiological levels of KSR1 to limit proliferative
signals and promote adipogenesis (36, 37). Therefore, KSR1
may be required to interact with MEK and moderate its activity when a biological effect requires restrained ERK activation
(e.g., during differentiation). These data indicate that specific
KSR1-effector interactions are key regulators of a cell’s replicative potential.
KSR1⫺/⫺ MEFs immortalize more readily than KSR1⫹/⫹
MEFs (Fig. 7). These data are reminiscent of the targeted
disruption of p16INK4a. While disruption of p16INK4a does not
immediately immortalize MEFs, knockdown of p16INK4a levels
using antisense RNA constructs accelerates the establishment
of immortalized cell lines (10). Furthermore, a greater proportion of p16INK4a⫺/⫺ cultures immortalize compared to wildtype cell results (61, 62). We observed that disruption of KSR1
prevented p16INK4a expression by RasV12. Thus, a defect in
p16INK4a/Rb pathway regulation may be a central contributor
to the accelerated immortalization of KSR1⫺/⫺ MEFs.
While we observed only a slight difference in the low-density
proliferative rate between KSR1⫺/⫺ and KSR1⫹/⫹ MEFs at
passage 5 (Fig. 7B), Lozano et al. reported a 50% reduction in
the proliferative rate of early-passage KSR1⫺/⫺ MEFs (42).
Their studies, however, were conducted at a population doubling of ⬍6, which corresponds to our MEFs at passages 1 to
3. Although we have not conducted low-density proliferative
studies at these early passages, our data are consistent with
low-passage-number KSR1⫺/⫺ MEFs showing decreased cell
proliferation compared to KSR1⫹/⫹ MEFs. When low-density
proliferative studies were seeded at passage 10, 15, or 18,
however, we observed increased proliferation in KSR1⫺/⫺
MEFs beginning around day 7 (Fig. 7B). These data would
indicate that KSR1⫺/⫺ MEF cultures at passages 10, 15, and 18
already contain immortal cells, which are detectable when the
MEFs were allowed to grow at a low density.
Premature senescence has been proposed as a tumor-suppressive mechanism, and escape from cellular senescence is
one of several events which predispose cells toward oncogenic
transformation (9). These data suggest that KSR1 might function to limit tumor susceptibility, since its deletion impedes
cellular senescence. Furthermore, an inefficient senescence response resulting from disruption of KSR1 might facilitate tumor progression induced by oncogenic mutations that are not
dependent upon Ras regulation of the Raf/MEK/ERK cascade. However, when assessing the transforming potential of
RasV12 in KSR1⫺/⫺ MEFs, we and others have found that
KSR1 is necessary for RasV12-mediated transformation in both
primary (42) and immortal (37) MEFs, indicating that KSR1 is
a positive modifier of tumorigenesis. This ostensible dual role
for KSR1 may result from its function as a molecular scaffold
for the Raf/MEK/ERK cascade. Signaling through the Raf/
MEK/ERK cascade moderates cell fate decisions depending
upon cellular context. Control of signal output through molecular scaffolds has been proposed as one of several nodes directing cell fate (35, 36). In both primary and immortal MEFs,
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